雷公藤甲素通过抑制破骨细胞生成预防骨丢失的研究

doi:10.13418/j.issn.1001-165x.2023.1.14

中国临床解剖学杂志 ›› 2023, Vol. 41 ›› Issue (1): 77-80.doi: 10.13418/j.issn.1001-165x.2023.1.14

雷公藤甲素通过抑制破骨细胞生成预防骨丢失的研究

陈俊泽¹，俞辉²，肖进²*

1.南方医科大学南方医院白云分院，广州 510420； 2.广东省人民医院，广州 510080

收稿日期:2021-10-22 出版日期:2023-01-25 发布日期:2023-02-08
通讯作者: 肖进，主任医师， E-mail：6627121@qq.com
作者简介:陈俊泽（1981-），男，广东人，副主任医师，研究方向：骨质疏松、创伤骨科，E-mail：3248615302@qq.com
基金资助:
广东省中医药局科研项目（20191005）；广州市科技计划项目（202102080222）

Triptolide prevents bone loss by inhibiting osteoclastogenesis

Chen Junze¹, Yu Hui², Xiao Jin²*

1. Baiyun Branch, Southern Hospital of Southern Medical University, Guangzhou 510420, China; 2. Guangdong Provincial People's Hospital, Guangzhou 510080, China

Received:2021-10-22 Online:2023-01-25 Published:2023-02-08

摘要/Abstract

摘要： 目的探讨雷公藤甲素抗骨质疏松的作用及机制。方法建立大鼠老年性骨质疏松模型。40只22月龄雄性SD大鼠随机分为雷公藤甲素（每天15 μg/kg腹腔注射）治疗组和生理盐水对照组（每天15μg/kg腹腔注射），连续8周。采用显微CT分析胫骨近端骨松质的骨密度(BMD)和骨显微结构。WB检测成骨相关蛋白表达水平。TRACP-5b染色法测定破骨细胞数，同时检测骨吸收标志物表达水平。结果显微CT结果显示，雷公藤甲素治疗组大鼠骨密度、骨体积/总体积比值(Bv/Tv)、骨小梁厚度(Tb.Th)、骨小梁数目(Tb.N)、骨小梁间距(Tb.Sp)均显著高于对照组（P<0.05）。两组的成骨相关蛋白表达水平无明显差异，TRACP-5b染色显示雷公藤甲素减少了体内破骨细胞的数量（P<0.05），同时血液骨吸收标志物水平也明显降低（P<0.05）。结论雷公藤甲素通过抑制破骨细胞生成进而对老年性骨质疏松有保护作用。雷公藤甲素可能是治疗老年性骨质疏松症的一种可行方案。

关键词: 雷公藤甲素； , , 骨质疏松； , , 成骨细胞； , , 破骨细胞

Abstract: Objective To investigate the antiosteoporotic effect and mechanism of triptolide. Methods A rat model of senile osteoporosis was established. Forty 22-month-old male SD rats were randomly divided into a treatment group of triptolide (15 μg/kg per day intraperitoneally) and a control group of saline (15 μg/kg per day intraperitoneally) for 8 weeks treatment. Bone mineral density (BMD) and bone microstructure of the proximal tibial cancellous were analyzed by micro-CT. Western blot was used to detect the expression level of osteogenic-related proteins. The number of osteoclasts was measured by TRACP-5b staining, and the expression levels of bone resorption markers were also detected. Results Micro-CT results showed that BMD, bone volume/total volume ratio (Bv/Tv), bone trabecular thickness (Tb.Th), bone trabecular number (Tb.N), and bone trabecular spacing (Tb.Sp) in the rats treated with ryanodine were significantly higher than those in the control group (P<0.05). There was no significant difference in osteogenesis-related protein expression between the two groups, and TRACP staining result showed that triptolide reduced the number of osteoclasts in vivo (P<0.05), while blood bone resorption marker levels were also significantly lower (P<0.05). Conclusions Triptolide has a protective effect on age-related osteoporosis by inhibiting osteoclastogenesis. Which may be a feasible option for the treatment of senile osteoporosis.

Key words: Triptolide; , , Osteoporosis; , , Osteoblast; , , Osteoclast

中图分类号:

R285

陈俊泽, 俞辉, 肖进. 雷公藤甲素通过抑制破骨细胞生成预防骨丢失的研究[J]. 中国临床解剖学杂志, 2023, 41(1): 77-80.

Chen Junze, Yu Hui, Xiao Jin. Triptolide prevents bone loss by inhibiting osteoclastogenesis [J]. Chinese Journal of Clinical Anatomy, 2023, 41(1): 77-80.

参考文献 19

[1]	Rubin CD. Age-related osteoporosis[J]. Am J Med Sci, 1991,301(4):281-298. DOI: 10.1097/00000441-199104000-00012.
[2]	Heaney RP. Age-related osteoporosis in Chinese women[J]. Am J Clin Nutr, 1999,69(6):1291-1292. DOI: 10.1093/ajcn.
[3]	Maclaughlin EJ, Sleeper RB, McNatty D, et al. Management of age-related osteoporosis and prevention of associated fractures[J]. Ther Clin Risk Manag, 2006,2(3):281-295. DOI: 10.2147/tcrm.2006.2.3.281.
[4]	丁超. 老年性骨质疏松症相关问题研究进展[J]. 中国骨质疏松杂志, 2016,22(3):372-375. DOI：10.3969/j.issn.1006-7108.2016.03.025.
[5]	Compston JE, McClung MR, Leslie WD. Osteoporosis[J]. Lancet, 2019,393(10169):364-376. DOI: 10.1016/S0140-6736(18)32112-3.
[6]	Wang Y, Wang B, Yang X. The Study of Cellular Mechanism of Triptolide in the Treatment of Cancer, Bone Loss and Cardiovascular Disease and Triptolide's Toxicity[J]. Curr Stem Cell Res Ther, 2020,15(1):18-23. DOI: 10.2174/1574888X14666190301155810.
[7]	Park B. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells[J]. Biochimie, 2014,105:129-136. DOI: 10.1016/j.biochi.2014.07.003.
[8]	Cui J, Li X, Wang S, et al. Triptolide prevents bone loss via suppressing osteoclastogenesis through inhibiting PI3K-AKT-NFATc1 pathway[J]. J Cell Mol Med, 2020,24(11):6149-6161. DOI: 10.1111/jcmm.15229.
[9]	彭坤. 骨质疏松性骨折治疗效果的改善：研究现状及策略分析[J]. 中国组织工程研究, 2022, 26(6):1027-1032. DOI: 10.12307/2022.189.
[10]	张文静. 骨质疏松治疗的相关研究进展[J]. 中国老年保健医学, 2020,18(04):101-102. DOI: 10.3969/j.issn.1672-2671.2020.04.033.
[11]	井莹莹, 王一力, 苏佳灿. 骨微环境对骨质疏松性骨折骨愈合的作用及其机制[J]. 中华创伤杂志, 2021, 37(8):683-687. DOI: 10.3760/cma.j.cn501098-20210331-00215.
[12]	邓飞飞, 宋强, 张成涛, 等. 骨质疏松相关分子病因及治疗研究进展[J]. 中华实验外科杂志, 2021,38(6):1186-1188. DOI: 10.3760/cma.j.cn421213-20201023-01379.
[13]	林若慧, 李生强, 陈娟, 等. 长链非编码RNA的中医药治疗骨质疏松症研究进展[J]. 中国骨质疏松杂志, 2021,27(9):1395-1399. DOI: 10.3969/j.issn.1006-7108.2021.09.029.
[14]	Ogbechi J, Clanchy FI, Huang YS, et al. IDO activation, inflammation and musculoskeletal disease[J]. Exp Gerontol, 2020,131:110820. DOI: 10.1016/j.exger.2019.110820.
[15]	Lacativa PG, Farias ML. Osteoporosis and inflammation[J]. Arq Bras Endocrinol Metabol, 2010,54(2):123-132. DOI: 10.1590/s0004-27302010000200007.
[16]	Fang H, Zhang H, Wang Z, et al. Systemic immune-inflammation index acts as a novel diagnostic biomarker for postmenopausal osteoporosis and could predict the risk of osteoporotic fracture[J]. J Clin Lab Anal, 2020,34(1):e23016. DOI: 10.1002/jcla.23016.
[17]	李晶芳, 韩蕊, 殷宏庆, 等. 雷公藤治疗肾脏疾病及其毒副作用的研究进展[J]. 中国实验方剂学杂志, 网络首发时间：2021-05-20. DOI: 10.13422/j.cnki.syfjx.20211305.
[18]	Kitzen JJ, de Jonge MJ, Lamers CH, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours[J]. Eur J Cancer, 2009,45(10):1764-1772. DOI: 10.1016/j.ejca.2009.01.026.
[19]	Yuan Z, Zhang H, Hasnat M, et al. A new perspective of triptolide-associated hepatotoxicity: Liver hypersensitivity upon LPS stimulation[J]. Toxicology, 2019,414:45-56. DOI: 10.1016/j.tox.2019.01.005.

雷公藤甲素通过抑制破骨细胞生成预防骨丢失的研究

Triptolide prevents bone loss by inhibiting osteoclastogenesis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 19

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	江剑宏, 段仁鹏, 李晓锋. 国人胆道三维重建解剖变异应用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 1-4.
[2]	郭红志, 王瑜, 张加琪, 梁海彬, 马梓玮, 冯伟, 吴忧, 司子燚. 血管铸型结合CT三维模型评估先兆子痫胎盘血管结构[J]. 中国临床解剖学杂志, 2024, 42(1): 5-10.
[3]	李佳伟, 张静, 李灿然, 兰文杰, 籍庆余, 郭志勇, 张云凤, 刘启, 陈清威, 李筱贺. 蒙古族人群股骨近端解剖参数X线测量[J]. 中国临床解剖学杂志, 2024, 42(1): 11-16.
[4]	李琨, 张燕, 郭冉, 郝咪咪, 吴轩宇, 徐艺芳, 王超群, 马文童, 张灵淇, 杨宏宇, 李志军, 张少杰, 王星. 儿童及青少年枕颈角与后枕颈角数字化测量及其临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 17-20.
[5]	李文, 杨思艺, 黄蕾, 卿霁雯, 蒋松涛, 张磊. 基于MRI探讨Lisfranc韧带的形态学特点及临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 21-25.
[6]	李凡凡, 徐阳, 王晓旭. 紫草素调节Nrf2/HO-1信号通路对实验性大鼠肉芽肿性小叶性乳腺炎的治疗作用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 26-32.
[7]	王兴航, 丁佳媛, 李放, 包翠芬, 阎丽菁. 人参皂苷Rg1通过抑制NLRP3炎症小体途径减轻氧糖剥夺/复供后小胶质细胞炎症反应[J]. 中国临床解剖学杂志, 2024, 42(1): 33-41.
[8]	程莹莹, 武建军, 蔡海燕, 焦旭文, 马江波, 丁银秀. 体外炎性诱导星形胶质细胞激活及功能分析[J]. 中国临床解剖学杂志, 2024, 42(1): 42-46.
[9]	祁志, 杨力, 贾秋叶, 陈浩伦, 段兆达, 吴春云. 依达拉奉经MAPKs通路对脂多糖激活的小胶质细胞Sirt3表达调控[J]. 中国临床解剖学杂志, 2024, 42(1): 47-53.
[10]	张晶晶, 王洪新. 黄芩苷通过PDGF/P38 MAPK信号通路对肺动脉高压大鼠的保护作用[J]. 中国临床解剖学杂志, 2024, 42(1): 54-58.
[11]	乐钦, 陈荣丽, 熊婧熙, 王婷怡, 蔡志恒, 易秋实, 曾心怡. 白芨多糖对大鼠跨区皮瓣choke区的影响[J]. 中国临床解剖学杂志, 2024, 42(1): 59-64.
[12]	李笑予, 张磊, 付磊, 李东波, 汪国友. 三步接骨法治疗Sanders Ⅱ型跟骨骨折的有限元研究[J]. 中国临床解剖学杂志, 2024, 42(1): 65-70.
[13]	吴研飞, 马剑雄, 卢斌, 王颖, 柏豪豪, 靳洪震, 马信龙. CT后处理技术重建CT值与终板抗压强度的相关性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 71-76.
[14]	庄万强, 唐毅, 骆勇刚, 张辉. 关节镜联合胫骨高位截骨术对髌骨位置及髌股关节功能影响的早中期回顾性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 77-82.
[15]	罗鹰, 窦伟誉, 吴小杭, 陈璟昆, 彭昌贵, 潘剑英 . 微创海马钢板内固定治疗跟骨骨折并发症的影响因素[J]. 中国临床解剖学杂志, 2024, 42(1): 83-88.